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Objectives: To determine whether previously undetected occult micrometastasis (MM) or isolated tumor cells
(ITC) is associated with increased recurrence odds in stage I-II endometrioid adenocarcinoma.
Methods: Women with recurrent stage I/II EC who had complete pelvic and para-aortic were identified as the
outcome of interest. A case-control study was designed with the exposure defined as occult MM/ITC not seen on
original nodal pathology. Controls were found by frequency-matching in a 1:2 case control ratio. Original nodal
slides were re-reviewed, stained and tested with immunohistochemical to detect occult MM/ITC and the odds of
associated recurrence was calculated.
Results: Of 153 included, 50 with and 103 without recurrence, there was no difference in age (p = 0.46), race (p
= 0.24), stage (p = 0.75), FIGO grade (p = 0.64), lymphovascular space invasion (LVSI); p = 1.00, or GOG 99
high-intermediate risk (HIR) criteria (p = 0.35). A total of 18 ITC (11.8%) and 3 MM (2.0%) not previously
identified were found in 19 patients. Finding occult MM/ITC was not associated with more lymph nodes (LN)
removed (p = 0.67) or tumor grade (p = 0.48) but was significantly associated with stage (p < 0.01). LVSI (p =
0.09) and meeting high-intermediate risk criteria (p = 0.09), were closely associated but not statistically sig
nificant. Isolated ITC were not associated with increased odds for recurrence (OR 0.71, CL: 0.20 – 2.22, p =
0.57), recurrence free survival (RFS) (p = 0.85) or overall survival (OS) (p = 0.92).
Conclusions: In early-stage EC, identification of occult MM or ITC is uncommon and associated with stage. The
presence of ITC was not associated with increased odds of recurrence. Adjusting stage or treatment may avoided
based on ITC alone. Isolated MM were rare in our population, and further investigation is warranted.

1. Introduction

that frequently identifies occult MM/ITC without evidence of macro
metastatic disease (Ballester et al., 2011; Rossi et al., 2017). MM are
defined as metastases>0.2 mm and<2.0 mm, while ITC are small tumor
deposits < 0.2 mm in largest diameter. In breast cancer, SLNB has been a
standard procedure worldwide for decades. Several published studies
serve as guidelines on management and prognostication based on the
presence of occult MM/ITC in axillary SLNB (Weaver et al., 2011; de
Boer et al., 2010; Giuliano et al., 2011; Donker et al., 2014). Increased
use of SLNB and pathological ultra-staging has increasingly identified
regional LN involvement in EC (Backes et al., 2019). However, the ab
solute clinical risk of recurrence associated with finding MM and ITC in
the absence of macro-metastatic (>2mm) LN in EC is not yet established.

Endometrial cancer (EC) is the most common gynecologic malig
nancy in the United States. Prognostic factors include stage, histology,
tumor grade, LVSI, and lymph node (LN) metastasis (Boronow et al.,
1984; Creasman et al., 1987; DiSaia et al., 1985). Based on these factors,
recurrence risk is stratified from low- to high-intermediate risk (HIR)
and guides adjuvant treatment including external beam pelvic radiation
(EBRT) or vaginal cuff brachytherapy (VCB) (Keys et al., 2004; Nout
et al., 2010; de Boer et al., 2018). Full pelvic and para-aortic lympha
denectomy (PPLND) in clinical stage I EC is gradually being replaced by
the adoption of sentinel lymph node biopsy (SLNB) with ultra-staging
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Borrowing from breast and colorectal cancer data (Weaver et al.,
2011; de Boer et al., 2010; Sloothaak et al., 2014), the International
Federation of Obstetrics and Gynecology (FIGO) 2009 EC staging and
the American Joint Committee on Cancer (AJCC) both currently upstage
clinical stage I EC to a stage IIIC based on the findings of lymph node
MMs, but not ITC. The AJCC designated a new category pN0(i + ) based
on the finding of ITC detected in ultra-staged LN, which leaves the door
open for increased adjuvant treatment based on degree of clinical
concern (Olawaiye and Mutch, 2018). Macrometastasis is an important
diagnostic factor in prescription of adjuvant treatment of EC (Milgrom
et al., 2014). However, there is no consensus on the benefit of adjuvant
treatment with the finding of occult MM/ITC in EC. Current practices
vary amongst physicians and institutions, particularly as SLNB have
become standard practice for many. Our study sought to determine if the
presence of occult MM/ITC conferred an increased odd of recurrence in
otherwise usually treated EC.

(LVM), including both occult MM or ITC on original LN pathology.
Baseline demographic, surgical, pathologic, and outcome data were
collected. To analyze potential differences in treatment that could affect
odds ratio (OR) for recurrence, we collected detailed adjuvant treatment
information for all cases and controls.
Pathological methods: H&E stained glass slides from each case were
reviewed to verify all LN sections. Paraffin blocks were recut and stained
using pan-cytokeratin (AE1/AE3, Ventana) immunohistochemical (IHC)
stain, Fig. 1. Following staining, slides were reviewed using conven
tional light microscopy by a blinded gynecologic pathologist. Slides
were scored as “positive” for occult malignant cells if any tumor specific
IHC panCK positive cells were identified, or “negative” if no such tumor
cells were identified. Cases which were scored as positive were then reexamined by routine H&E to determine if the occult positive cells were
detectable by regular staining (false-negative by initial report) or truly
occult and undetectable by routine sampling. Positive cases were further
sub-classified as ITC or MM.
Statistical Analysis: Demographic, clinicopathologic, treatment and
survival factors were collected and tested for differences. Categorical
characteristics were compared using chi-squared tests or Fisher’s exact
test. Continuous variables were compared with two-sample t-tests, or
Wilcoxon rank-sum tests. Ordinal and rank-based variables were
compared using Wilcoxon rank-sum tests. The effect of LVM on presence
or absence of recurrence was modeled using logistic regression, adjust
ing for any variables found to be significantly associated with case/
control status in univariate analyses, as well as all variables used in the
frequency matching between cases and controls. Time to recurrence was
modeled using Cox proportional-hazards models, with similar adjust
ment terms. To evaluate whether recurrence was attributed to adjuvant
treatment, patients meeting HIR from each cohort were compared by
treatment appropriateness to test for differences. Likewise, we deter
mined whether the presence of MM/ITC was associated with greater
odds of receiving treatment before and after adjusting for GOG99 highrisk status. It is important to note that all cases and controls were

2. Materials and methods
Study Design: We designed an IRB approved (OU-IRB#9601) casecontrol study to determine the effect that occult MM/ITC has on the
odds of recurrence. We included women diagnosed with stage I/II
endometrioid EC following hysterectomy and PPLND from July 2008 to
July 2018 with pathology-reported LN nodes at time of surgery. Women
with non-endometrioid histology, positive LN, stage III or IV disease, or
incomplete PPLND were excluded. Our institution did not routinely
perform SLNB for endometrial cancer patients until after the study
period, thus, PPLND was standard practice during this time. The
outcome of interest was clinically confirmed EC recurrence; these pa
tients were defined as cases. The control group was defined as those
without recurrence ≥ 24 month (m) following surgery. Cases and con
trols were frequency-matched in a 1:2 case to control ratio based on
established prognostic factors including age, FIGO stage, grade, and
LVSI. The exposure was previously undetected low volume metastases

Fig. 1. Possible isolated tumor cells on PanCK at 4x and 20x magnification, not visualized on H&E 4x and 20x.
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dispositioned to adjuvant treatment agnostic to SLNB status, but rather
as fully staged, stage I or II EC. In accordance with the journal’s
guidelines, we will provide our data for the reproducibility of this study
in other centers if such is requested.

Table 1
Baseline characteristics for cases and controls.

3. Results
All University of Oklahoma patient scheduled for surgical staging
hysterectomy with full PPLND from 2008 to 2018 (n = 1024) were
screened. Of those, 437 (42.7%) met inclusion criteria. Whereas 45
(4.4%) had incomplete surgical pathology, 181 (17.7%) were missing
PPLND for evaluation and 128 (12.5%) were benign or pre-invasive. A
total of 134 patients had non-endometrioid histology (13.1%), and
among the endometrioid subtypes, 87 (8.5%) had stage III disease, and
of those 60 (5.9%) had macrometastasis to their LN, making them IIIC
disease, and 12 (1.2%) had stage IV disease (SupFig1).
Of the 437 subjects meeting inclusion criteria, 52 (11.9%) had a
confirmed recurrence and 50 had complete demographic and clinico
pathologic data and served as study cases. Based on these 50 cases,
controls were identified from the remaining pool of eligible subjects and
frequency matched at an approximate ratio of 1:2 based on tumor grade,
tumor stage (equal frequencies of stage IA, IB and stage II), median age
per stage group, and presence of LVSI.
Of the 153 cases and controls identified, 152 pathologic cases were
reviewed; one control was excluded due to slide degradation, this is
represented by 2219 slides (average 14.6 slides per case/control, 3.4
slides per dissection site). A total of 162 (7.3%) blocks belonging to the
series were not available for sectioning, leaving 2057 panCK slides for
evaluation. Where slide quality was inadequate, repeat staining was
requested. Final slide review identified 18 previously unseen ITC and 3
MM among 19 cases and controls (12.5%); two patients had both MM
and ITC, leaving 16 cases of ITC alone (SupFig 2). Of the 2057 IHC slides
examined, 36 contained IHC positive cells determined to be most likely
tumor cells, with an average of 2.25 slides per positive subject (Fig. 1).
Two of the MM cases were found on retrospective review to be false
negatives and were able to be identified on routine H&E.
A total of 153 participants were included for analysis, 50 cases of
recurrence and 103 without recurrence at a minimum of 24 m. At time of
pathology evaluation, one control was non-evaluable. Table 1 shows the
demographics. The majority (77.8%) of patients had minimally invasive
surgery for predominately stage IA disease (46.4%). Grade 2 was most
frequently observed, as was the absence of LVSI. Upon final pathology
reporting, most patients (64.1%) met HIR criteria according to GOG 99;
this is expected, as this was a population matched for the outcome of
recurrence, thus enriched for HIR patients. Cases and controls were well
balanced according to BMI (p = 0.20), race (p = 0.27), performance
status (p = 0.21), surgical type (p = 0.80) and frequency of positive
intraperitoneal washings 6.0% vs 5.9% (p = 1.00), table 1. However,
interestingly, we found that there were significantly more LN removed
in the recurrent cases compared to controls (22 vs 19; p < 0.05). Median
follow-up between cases and controls was 53.3 versus 62.3 m, respec
tively, but was not significantly different, p = 0.06. For the controlled
characteristics, there was no significant difference in age, (p = 0.46),
stages IA vs IB vs II (p = 0.75), FIGO grade (p = 0.64), presence of LVSI,
p = 1.00, or meeting HIR criteria by GOG-99, p = 0.36 (table 1).
Due to the relative rarity of MM alone, we looked at those with any
occult LVM (MM and/or ITC) and those with ITC alone. Between cases
and controls, there were 6 (12.0%) and 13 (12.7%) cases of occult LVM,
respectively, which was not different between cohorts, p = 1.00. When
looking at the presence of ITC alone, there remained no significant
difference between cases and controls, p = 1.00. There were also no
significant differences in those with and without ITC alone for de
mographic factors, surgical approach, or number of LN removed
(Table 2). ITC positive status tended towards association with presence
of LVSI (p = 0.07), however, this was not statistically significant. Pres
ence of occult ITC was found to be significantly associated with tumor

Characteristic

All
N = 153

Cases
n = 50

Controls
n = 103

Age Median [25%,
75%]
Race/Ethnicity
AI/PI
Asian/Middle-Eastern
Black/non-Hispanic
Hispanic, LatinX
White/non-Hispanic
Payer status
IHS
Medicaid
Medicare/Medicare
combo
Not insured/sooner
care
private
N missing
BMI Median [25%,
75%]
Performance status
0
1–2
Diabetes
Cardiovascular
Disease
Surgery Type
Minimally Invasive
Laparotomy
Stage
Ia
Ib
II
Grade
1
2
3
LVSI
DOI (%) Mean
Tumor size (cm)
Washings þ
Nodes removed Mean
GOG-99 High Risk
MM/ITCþ
ITC þ alone
FU (m) Median [25%,
75%]

64.0 [59.0,
72.0]

62.5 [57.0,
71.8]

64.0 [59.0,
72.5]

9 (5.9%)
5 (3.3%)
6 (3.9%)
4 (2.6%)
129 (84.3%)

3 (6.0%)
0
1 (2.0%)
1 (2.0%)
45 (90.0%)

6 (5.8%)
5 (4.9%)
5 (4.9%)
3 (2.9%)
84 (81.6%)

5 (3.3%)
1 (0.7%)
88 (58.3%)

4 (8.2%)
0 (0.0%)
24 (49.0%)

1 (1.0%)
1 (1.0%)
64 (62.7%)

10 (6.6%)

2 (4.1%)

8 (7.8%)

47 (31.1%)
2
33.0 [27.7,
38.9]

19 (38.8%)
1
34.0 [28.1,
41.8]

28 (27.5%)
1
31.4 [27.6,
37.7]

141 (92.2%)
12 (7.8%)
45 (29.4%)
31 (20.3%)

44 (88.0%)
6 (12.0%)
18 (36.0%)
10 (20.0%)

97 (94.2%)
6 (5.8%)
27 (26.2%)
21 (20.4%)

119 (77.8%)
34 (22.2%)

40 (80.0%)
10 (20.0%)

79 (76.7%)
24 (23.3%)

71 (46.4%)
66 (43.1%)
16 (10.5%)

22 (44.0%)
23 (46.0%)
5 (10.0%)

49 (47.6%)
43 (41.7%)
11 (10.7%)

26 (17.0%)
79 (51.6%)
48 (31.4%)
50 (32.7%)
44.1 ± 30.4
4.0 ± 2.7
9 (5.92%)
19.8 ± 7.8
98 (64.1%)
19 (12.4%)
16 (10.5%)
59.6 [43.6,
79.9]

8 (16.0%)
25 (50.0%)
17 (34.0%)
16 (32.0%)
47.1 ± 32.3
4.3 ± 2.7
3 (6.00%)
21.9 ± 9.2
29 (58.0%)
6 (12.0%)
5 (10.0%)
53.3 [28.5,
76.5]

18 (17.5%)
54 (52.4%)
31 (30.1%)
34 (33.0%)
42.7 ± 29.4
3.8 ± 2.7
6 (5.88%)
18.9 ± 7.0
69 (67.0%)
13 (12.7%)
11 (10.8%)
62.3 [48.1,
84.4]

pvalue
0.46
0.27

0.22

0.21
0.21
0.29
1.00
0.80
0.75

0.64

1.00
0.40
0.30
1.00
<0.05
0.36
1.00
1.00
0.06

*PI (Pacific Islander), AI (American Indian), HIS (Indian Health Service), BMI
(body mass index), CV (cardiovascular), LVSI (lymphovascular space invasion),
DOI (depth of invasion), FU (length of follow-up)
p-values unadjusted for matching factors in case-control design

stage and depth of invasion (DOI), and tumor size, 5.3 cm vs 3.8 cm, all
p < 0.05. Finding occult ITC was marginally associated with being GOG99 HIR but this was not statistically significant (p = 0.07).
In the cohort with occult MM/ITC (n = 19) there were 6 recurrences,
compared to 44 in those with no occult MM/ITC (n = 133), representing
31.6% vs 33.1% of patients, respectively. After adjusting for total LN
removed, presence of MM/ITC was not associated with recurrence (OR
1.11, CL: 0.40–3.37; p = 0.85), Table 3. The unadjusted effect of occult
MM/ITC on OS and RFS was modeled and plotted with Kaplan-Meier
curves, and neither RFS (p = 0.87) nor OS (p = 0.89) was associated
with the presence of occult LVM (Supplementary figure 3). After
adjusting for total LN, this was unchanged. When investigating the effect
of finding occult ITC alone, we found that neither RFS (p = 0.85) nor OS
(p = 0.92) differed when compared to ITC negative populations (Sup
plementary figure 3).
To assess the potential for confounding, differences in treatment
according to recurrence and MM/ITC status were examined. A total of
29 cases (58.0%) of recurrence met GOG-99 HIR criteria, whereas n = 69
3
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Table 2
Factors associated with occult low volume metastases.
Characteristic (N = 153)

MM/ITC(+)
n = 19

MM/ITC(-) n = 133

Age Median [25%, 75%]
Race/Ethnicity
AI/PI
Asian/Middle-Eastern
Black/non-Hispanic
Hispanic, LatinX
White/non-Hispanic
BMI Median [25%, 75%]
Diabetes
Surgery Type
Minimally Invasive
Laparotomy
Stage
Ia
Ib
II
Grade
1
2
3
LVSI
DOI (%) Mean
Tumor size (cm)
Washings þ
Nodes removed Mean
GOG-99 High Risk

63.0 [58.0, 67.5]

64.0 [59.0, 73.0]

1 (5.3%)
0 (0.0%)
0 (0.0%)
1 (5.3%)
17 (89.5%)
34.8 [30.0, 42.3]
7 (36.8%)

8 (6.0%)
5 (3.8%)
6 (4.5%)
3 (2.3%)
111 (83.5%)
32.7 [27.7, 37.9]
38 (28.6%)

15 (78.9%)
4 (21.1%)

103 (77.4%)
30 (22.6%)

3 (15.8%)
10 (52.6%)
6 (31.6%)

67 (50.4%)
56 (42.1%)
10 (7.5%)

2 (10.5%)
14 (73.7%)
3 (15.8%)
10 (52.6%)
66.3 ± 21.4
5.3 ± 2.7
1 (5.26%)
20.5 ± 6.2
16 (84.2%)

24 (18.0%)
65 (48.9%)
44 (33.1%)
40 (30.1%)
41.0 ± 30.3
3.8 ± 2.7
8 (6.06%)
19.7 ± 8.1
81 (60.9%)

p-value
0.50
0.74

0.07
0.64
1.00

<0.01

0.48

0.09
<0.01
0.02
1.00
0.67
0.09

ITC only(+)
n = 16

ITC only(-)
n = 136

p-value

63.5 [59.0, 67.2]

64.0 [58.0, 73.0]

0 (0.0%)
0 (0.0%)
0 (0.0%)
1 (6.2%)
15 (93.8%)
33.5 [28.3, 43.1]
7 (43.8%)

9 (6.6%)
5 (3.7%)
6 (4.4%)
3 (2.2%)
113 (83.1%)
33.1 [27.7, 38.0]
38 (27.9%)

12 (75.0%)
4 (25.0%)

106 (77.9%)
30 (22.1%)

2 (12.5%)
8 (50.0%)
6 (37.5%)

68 (50.0%)
58 (42.6%)
10 (7.4%)

2 (12.5%)
11 (68.8%)
3 (18.8%)
9 (56.2%)
66.3 ± 20.8

24 (17.6%)
68 (50.0%)
44 (32.4%)
41 (30.1%)
41.5 ± 30.4

0.07
<0.01

1 (6.25%)
20.9 ± 6.0
14 (87.5%)

8 (5.93%)
19.7 ± 8.1
83 (61.0%)

1.0
0.55
0.07

0.73
0.47(2)

0.14
0.25
0.76

<0.01

0.58

* PI (Pacific Islander), AI (American Indian), BMI (body mass index), LVSI (lymphovascular space invasion), DOI (depth of invasion), MM (micrometastases), ITC
(isolated tumor cells)
(2) P-value computed for White vs others

see table 4.
For those that did recur there were no significant differences in the
patterns of recurrence according to MM/ITC status. There was a larger
proportion of vaginal recurrences in those without MM/ITC compared to
those with (5.3% vs 11.3%, p = 0.67). Pelvic and nodal recurrences were
relatively similar according to MM/ITC status as were rates of upper
abdominal and/or distant metastases (SupTab2).

Table 3
a Logistic regression for recurrence predicted by MM/ITC. b: Logistic regression
for recurrence predicted by ITC.
Recurrence
a.
Yes vs. No
b.
Yes vs. No

OR

95% LCL

95% UCL

0.87

0.27

2.59

0.71

0.20

2.22

Table 4
Adjuvant treatment by occult ITC/MM status.

The effect of MM/ITCs on recurrence was modeled using logistic regression,
adjusting for total LNs removed and characteristics used for frequency matching
(age, stage, grade, and LVSI). Adjusting for these factors, presence of MM/ITCs
was not significantly associated with recurrence (p = 0.81).
The effect of ITCs on recurrence was modeled using logistic regression, adjusting
for total LNs removed and characteristics used for frequency matching (age,
stage, grade, and LVSI). Adjusting for these factors, presence of ITCs was not
significantly associated with recurrence (p = 0.57).
*Micrometastases/Isolated tumor cell (MM/ITC), Lower confidence limit (LCL),
Upper confidence limit (UCL)

(67.0%) of controls met criteria, p = 0.36. We found no significant
difference in surgery type (p = 0.80), receipt of adjuvant treatment (p =
0.66), or receipt of adjuvant treatment according to GOG-99 HIR criteria
between cases and controls (78.0% vs 82.5%; p = 0.65). In the subgroup
of HIR patients, n = 98, 64.1%, we found no difference in receipt of
adjuvant treatment according to GOG99 criteria between those of HIR
that recurred compared to those that did not, p = 0.88 (SupTab1). The
receipt of any radiation (VCB and/or EBRT) was found to be signifi
cantly higher in the + MM/ITC cohort. However, when adjusting for
GOG99 high-risk criteria, presence of MM/ITC was not significantly
associated with patients receiving more radiation therapy (p = 0.33) but
was marginally associated with higher odds of receiving systemic
chemotherapy (OR = 2.52 [0.8, 7.4]; p = 0.10). It is important to note,
that at our institution, during this study period we were enrolling widely
into clinical trials that evaluated combination chemoradiation for high
risk early stage EC. For additional information on adjuvant treatment,

Treatment

MM/ITC
(+)
n = 19

MM/ ITC
(-)
(n =
133)

pvalue

p-value adjusted
for GOG-99 HIR
criteria

High Risk (GOG99
criteria)
Receipt of adjuvant
treatmentaccording to
HIR criteria
Clinical trial enrollment
GOG 249
RTOG 1203
RTOG-092
IIT of T/C × 3cycles + VCB

16
(84.2%)
17
(89.5%)

81
(60.9%)
106
(79.7%)

0.09

NA

0.53

0.53

7
(53.8%)
0
3
1
3
5
(26.3%)
8
(42.1%)
7
(36.8%)
14
(73.7%)
2
(10.5%)

26
(37.7%)
7
13
1
5
20
(15.0%)
45
(33.8%)
26
(19.5%)
66
(49.6%)
4 (3.0%)

0.43

0.39

0.16

0.10

0.61

0.87

0.13

0.25

0.05

0.33

0.16

0.20

Systemic chemo
VCB
EBRT
Any Radiation
CisRT

*Gynecologic Oncology group (GOG), High intermediate risk (HIR), Radiation
therapy oncology group (RTOG), Investigator-initiated trial (IIT), Vaginal cuff
brachytherapy (VCB), External beam radiation therapy (EBRT), Radiation
therapy(RT), cisplatin (cis)
4
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4. Discussion

randomization, we minimized selection bias and detection bias by
controlling for known prognostic factors in EC recurrence risk and by
blinding our pathologist to case or control status. Lastly, the relatively
racially and ethnically homogenous study population weakens gener
alizability. Strengths of our study include use of a case-control design
which is best suited to investigate associations with rare outcomes such
as recurrent early-stage EC and studying a population in which full nodal
dissections were completed and presumed negative to minimize con
founding treatment effect. Additionally, we were able to review a high
number of slides with dedicated specialized gynecologic pathologists.
Implications for practice and future research: Many gynecologic
oncologists are already adjusting treatment based on MM and ITC. In the
survey of gynecologic oncology surgeons, 77.2% and 21.3% of re
spondents reported that MM and ITC should be treated as node positive
disease, respectively (Chambers et al., 2019), which makes investigation
of this topic relevant and timely. Outside of a well-funded, cooperative
group trial, definitive recommendation for adjuvant treatments based on
the presence of ultrastaged occult MM/ITC cannot be made. However,
solace can be found in the consistent reporting that occult MM/ITC
follows well established uterine high-risk factors such as DOI, LVSI,
tumor grade and size. As LVM are very likely molecularly driven, it is
important that we begin to understand EC according not only to histo
logic risk factors but within the context of molecular risk stratification.
As such, when deciding upon adjuvant treatment recommendations for
patients, the presence of occult MM/ITC should not be viewed in a
vacuum but rather in context with other clinicopathologic and molec
ular risk factors.
Conclusions: In an early stage, usually treated EC population,
identification of occult MM or ITC is uncommon and associated with
stage, DOI, tumor size and closely associated with the presence of LVSI
and meeting HIR GOG-99 criteria. The presence of ITC was not associ
ated with increased odds for recurrence, RFS, or OS.
Funding source:
Research reported in this publication was supported in part by a
Stephenson Cancer Center Trainee Research Award funded by the Na
tional Cancer Institute Cancer Center Support Grant P30CA225520
awarded to the University of Oklahoma Stephenson Cancer Center. The
content is solely the responsibility of the authors and does not neces
sarily represent the official views of the National Institutes of Health.
Precis: This is a timely case-control study that evaluates whether the
presence of previously undetected MM or ITC in otherwise standardly
treated early-stage endometrial cancer is associated with an increased
odd of recurrence.

Summary of main results: In our study, finding occult MM/ITC in
usually treated EC patients did not negatively impact odds of recurrence,
RFS or OS. Our data affirms that occult MM/ITC are uncommon. MM not
previously detected is even more rare and likely due to a false negative
H&E examination. Accepting that ex post facto ultra-staging introduces
confounding and Our data suggests that in the setting of ITC alone found
through ultrastaging, patients may be safely offered adjuvant treatment
according to risk stratification based on uterine factors (i.e. GOG99
criteria) and potentially spared systemic chemotherapy if ITC is their
only concerning feature.
Results in the context of published literature: Adoption of SLNB for
EC is popular as it offers decreased morbidity while allowing a sensitive
evaluation for otherwise unapparent nodal disease. In fact, a recent
survey of SGO members found that nearly 70% of respondents were
using SLNB for EC and that > 50% of those using SLNB for EC use it
regardless of tumor grade or histology (Chambers et al., 2019). How
ever, the increased detection of LVM provides more prognostic infor
mation but also mounts clinical uncertainty.
A beneficial outcome of patients randomized to systematic LND in
the Benedetti and ASTEC trials is that they received less adjuvant
treatment (ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C,
Parmar MK. , 2009; Panici et al., 2008). As current practice shifts to
SLNB, some women prescribed less treatment in these original EC trials
may increasingly be offered adjuvant treatment based on increased
detection of LVM. It has been repeatedly demonstrated that SLNB and
ultrastaging increases detection of nodal disease by 40–50% and that
nearly half of those detected are occult MM/ITCs (de Boer et al., 2010;
Holloway et al., 2016; Kim et al., 2013).
Holloway et al, evaluated the performance of SLNB compared to full
LND and found that the patients who underwent SLN mapping were
more likely to undergo combination radiotherapy and chemotherapy
(28.6% vs. 16.3%; p < 0.01) (Holloway et al., 2016). Plante et al. re
ported the prognosis of ITCs in EC; at median follow-up of 29 months,
the PFS of ITC and MM was 95.5%, 85.5%, respectively, which was
comparable to the node negative group cohort of 87.6% (Plante et al.,
2017). Of note, in this study, compared to Holloway et al, those with ITC
alone received significantly less chemotherapy and pelvic RT with
similar 3-year PFS outcomes as those that were node negative (Plante
et al., 2017). Pineda et al demonstrated PFS was also significantly worse
in the macrometastasis group (61.1%) compared to the LVM group
(71.4%) and negative lymph nodes (83.2%, p < 0.05), though those with
LVM did receive more adjuvant therapy (García Pineda et al., 2020;9
(6):1999.). Backes et al performed a prospective trial to determine the
detection rate of SLNB in clinically early-stage EC and prospectively
assessed occult MM/ITC in the ultrastaged cohort. For 10 patients with
occult MM/ITC, 5 were treated with adjuvant therapy based on clinical/
uterine factors alone and at the time of reporting, no recurrences were
noted (Backes et al., 2019). At the practice level, it remains unanswered
whether occult MM/ITC may be associated with additional metastases in
distal LN, though Multuni, et al, described distant occult LVM in 30% of
those with presumed isolated para-aortic nodes, 2.5% of their popula
tion (Multinu et al., 2019). Holloway found that 4 of the 12 with SLN
positive ITC also had positive non SLN, whereas Backes et al found that
none of the 10 pts with ITC had non SLN metastases. Similarly, in the
study by Plante et al, none of the patients with LVM had other positive
non-SLN (Backes et al., 2019; Holloway et al., 2016; Plante et al., 2017).
Low volume disease is more likely to be detected in patients with low
grade endometrioid endometrial cancer (Bogani et al., 2019). As the
prevalence of ITC is low in high risk EC, this potentially explains why
ITC is less likely to impact outcomes; leading to further questions as to
who confers benefit from increased adjuvant treatment of occult MM/
ITC.
Strengths and Limitations: Though this is a retrospective, singleinstitution study with the inherent risk for bias and non-
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